Literature DB >> 7115871

Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis.

J R Anderson, L Bernstein, M C Pike.   

Abstract

For survival probabilities with censored data, Rothman (1978, Journal of Chronic Diseases 31, 557-560) has recommended the use of quadratic confidence limits based on the assumption that the product of the 'effective' sample size at time t and the life-table estimate of the survival probability past time t follows a binomial distribution. This paper shows that the proposed confidence limits are asymptotically correct for continuous survival data. These intervals, as well as those based on the arcsine transformation, the logit transformation and the log(--log) transformation, are compared by simulation to those based on Greenwood's formula--the usual method of interval estimation in life-table analysis. With large amounts of data, the alternatives to the Greenwood method all produce acceptable intervals. On the basis of overall performance, the intervals suggested by Rothman are preferred for smaller samples. Any of these methods may be used to generate confidence sets for the median survival time or for any other quantile.

Keywords:  Demographic Analysis; Demographic Factors; Length Of Life; Life Table Method; Life Tables; Mathematical Model; Models, Theoretical; Mortality; Population; Population Dynamics; Research Methodology; Survivorship

Mesh:

Year:  1982        PMID: 7115871

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

1.  Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.

Authors:  Siqi Zhang; Mengge Zheng; Deheng Nie; Lili Xu; Huimin Tian; Mengmeng Wang; Wenjia Liu; Zhenbang Feng; Fujun Han
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

2.  Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.

Authors:  W Scheithauer; G Kornek; K Haider; W Kwasny; T Schenk; R Pirker; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.

Authors:  Julie M Vose; Shelly Carter; Linda J Burns; Ernesto Ayala; Oliver W Press; Craig H Moskowitz; Edward A Stadtmauer; Shin Mineshi; Richard Ambinder; Timothy Fenske; Mary Horowitz; Richard Fisher; Marcie Tomblyn
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

4.  Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.

Authors:  Nikolas Tsavaris; Christos Kosmas; Panagiotis Gouveris; Kostadinos Gennatas; Aris Polyzos; Despina Mouratidou; Heracles Tsipras; Helias Margaris; George Papastratis; Evanthia Tzima; Nikitas Papadoniou; Gavrilos Karatzas; Efstathios Papalambros
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

5.  Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Authors:  Sebastian Mondaca; Matthew Margolis; Francisco Sanchez-Vega; Philip Jonsson; Jamie C Riches; Geoffrey Y Ku; Jaclyn F Hechtman; Yaelle Tuvy; Michael F Berger; Manish A Shah; David P Kelsen; David H Ilson; Kenneth Yu; Zoe Goldberg; Andrew S Epstein; Avni Desai; Vincent Chung; Joanne F Chou; Marinela Capanu; David B Solit; Nikolaus Schultz; Yelena Y Janjigian
Journal:  Gastric Cancer       Date:  2018-08-07       Impact factor: 7.370

6.  Phase II study of amonafide in advanced breast cancer.

Authors:  W Scheithauer; C Dittrich; G Kornek; K Haider; W Linkesch; H Gisslinger; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

7.  Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.

Authors:  G V Kornek; K Haider; W Kwasny; M Hejna; M Raderer; S Meghdadi; D Burger; B Schneeweiss; D Depisch; W Scheithauer
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.

Authors:  Mi-Jung Kim; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2008-12-18       Impact factor: 4.430

9.  Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.

Authors:  G V Kornek; K Haider; W Kwasny; F Lang; G Krauss; M Hejna; M Raderer; G Weinländer; D Depisch; W Scheithauer
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

10.  Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.

Authors:  B Neri; G Cini; L Doni; C Fulignati; M Turrini; D Pantalone; E Mini; C De Luca Cardillo; L M Fioretto; A S Ribecco; R Moretti; M Scatizzi; G Zocchi; A Quattrone
Journal:  Br J Cancer       Date:  2002-08-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.